Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Premium
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • FemmeBreaking barriers and building confidence in investing
  • Learn about investing
    • Analysis SchoolLearn how to read and understand stock analysis
    • Investing SchoolGuides and lessons to grow your investing knowledge
    • Portfolio buildersInvesting knowledge for every level, from first steps to advanced portfolio strategies.
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Insider TransactionsTrack buying and selling activity by company insiders
    • Short SellingSee which listed companies have disclosed short interest
    • Virtual Analyst ChatAsk questions and get instant AI-powered investment insights
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Transcripts

Read transcripts of webcasts and audiocasts

Transcripts

Read transcripts of webcasts and audiocasts

All regions
Finland
Sweden
Denmark
Norway
Latest
Trending
Followed

Getinge, Audiocast with teleconference, 2024

By Inderes5/15/2024, 8:00 AM
Getinge

Disclaimer: This is a machine-generated transcript and may contain inaccuracies.

Mattias Perjos
00:01 - 12:49

Hi everyone, and welcome to this Capital Markets update. The purpose of the call today is to provide a bit more color on the recent letter from the FDA and what we plan to do about it. We will also discuss a new financial target and finish off with the Q&A session. So with that we can move directly to slide number two, please. So a week ago, on, uh, May 8th, uh, the FDA sent a letter to US healthcare providers concerning our cardiovascular products. They called out Cardiohelp, Cardiosave, and the HLS. Uh, there were no new findings or field actions referred to in this letter. And Getinge also does not have any new field safety corrective actions to report at this stage. Even so, the FDA recommends a transition to alternative products when possible. And in cases where that is not possible, uh, healthcare providers ought to stay with Getinge's products to make sure that patients do get treated. We can then switch to slide number three, please. So I just wanted to highlight what we do about this and the actions that we've taken. And we of course, take, uh, this recommendation from the FDA very seriously. And we have initiated immediate actions related to this. So in the short term and in alignment with the FDA, we will in the US suspend all promotional activities for Cardiohelp and Cardiosave. Uh, sales will only be done to customers who don't have available alternatives for these products. All customers will also be informed about the regulatory requirements regarding the indications for use of Cardiohelp, and for the installed base. We will continue to supply consumables and we will continue to service the hardware. Uh, outside of the US, we will continue to sell both consumables and hardware for Cardiosave and Cardiohelp in all markets where these products are approved. Uh, due to the importance of the US market, we, uh, we will of course have some negative financial impact from this. And it's too early to say, though, how much that is. It's something that we will need to monitor in the coming months when it comes to, uh, to customer behaviors and so on. So it depends on both internal and external factors. So, uh, finalizing the implementation of ongoing improvements, for example, is something that's completely in our hands, uh, whereas customer behavior, competitors' activities and receiving regulatory approval are external factors that we can only have a limited impact on. We then move to slide number four, please. So in the long term, uh, our plans have not changed. If they had not asked us to do anything that we were not already doing. So we are progressing accordingly and in line with what we have previously communicated. So where we are now is that we have worked down 90% of the quality record backlog, and there are no new material findings from this work. So the focus now is strongly on product updates to remediate the concerns that we are already well aware of. Furthermore, in the first quarter, we filed for approval of the new packaging solutions for HLS sets for the C market. As you probably remember, this has been one of the key areas of improvement that we've been working on for the last year. In parallel, the development of the next generation of Cardiohelp and Cardiosave is ongoing. So for Cardiohelp, you have updates. We aim for submission to the FDA towards the end of the first half of 2025, followed by an update and submissions for clearance of HLS sets as well for Cardiosave. Plus, the submission for the FDA is expected during the second half of 2025. So the product will be developed and ready by mid next year, and the submissions will be in the second half. We can then move to page number five. I wanted to take this opportunity to. To take a bit of a broader perspective on quality in acute care therapies. And from Getinge's perspective overall, you are hopefully aware that we do not have any particular challenges when it comes to surgical workflows and life science. So, in our two other business areas and also within acute care therapies, the challenges are related to cardiopulmonary and cardiac assist. So we've highlighted here a number of achievements and good progress that we see when it comes to regulatory areas in both the US, the EU, and China. So we have, for example, our Hemo Pro 3 that we received 510k clearance for in February of this year. We have approvals for our graft systems. We had the PMA for a covered stent system as well. We had the Server Air Light clearance in the middle of last year. And we recently had our Talis EMR with also advanced clinical guidance cleared, filed 510k on the 1st of April this year. And in Europe, we made good progress with transitioning to one notified body. We received EU MDR approval for our HLS Set Advanced on the 16th of February this year. And you can also see that we're making good progress when it comes to an uplift in the portfolio and the different aspects of compliance with MDR regulations. And in China, we had our EV systems approved as well. And very recently, our road to flow to new registrations also approved. So again, the quality challenges that we have are confined to cardiopulmonary and cardiac assist. We then moved to the next slide, please. Key for us, and I think one of the key strengths of Getinge as a company, is the global reach we have and the long-standing relationships that we have maintained for 120 years of serving our customers well. And in spite of the challenges in recent years, we have tried to maintain this customer-centric approach, which has had a good outcome. We had an updated customer survey a couple of weeks ago, and we can see that we are comparing favorably with the already good score that we had in 2021. We had a five percentage points increase now in 2023. So customer satisfaction remains a key core priority for us. And we continue to focus on further improving this in the coming years. We then move to page number seven, please, and start dissecting the growth prospects of Getinge in the coming years. So overall, we expect a 3 to 6% organic growth in net sales between now and 2028. There are some key factors baked into this projection. One of the assumptions is that there will be this negative financial impact from cardiopulmonary and cardiac assist that we were not aware of a week ago. However, we can also see that there's a normalization in mix towards higher margin products in both Life Science and also in surgical workflows. And when it comes to China, which has been one of the key uncertainties the last couple of years, here, we are expected to get back on the growth track, but we think the new normal here will be high single digits rather than mid-teens like we've seen before. And in all of this as well, productivity will continue to be of very high importance in the coming years to mitigate the inflationary pressure that we've seen. And, we will continue with a lot of the measures that we have done well for many years, like quality value engineering, portfolio pruning, consolidation of our supplier base, and so on. We also do expect some additional growth from acquisitions. We continue to actively look in selective areas. And, we believe that we have, despite the acquisitions that we did in the fourth quarter of last year, some room to maneuver still, and our aim is to be able to do this without breaching the two and a half times leverage. We can then move to page number eight, please. So I wanted to take you through the three different business areas as well. So a bit more of a granular perspective on this. So we start with acute care therapies. And this is the business area that accounts for about 50% of Getinge's sales. And half of that is in the Americas. So margin-wise in this business area, we are now back at pre-pandemic levels. So the improvement journey will need to restart from this level. And when it comes to the growth for 2024 through 2028, acute care therapies is expected to grow 3 to 5%. In addition to the impact from the product challenges and cardiac assist and cardiopulmonary, the projection here assumes that we will benefit from the ongoing consolidation in the ventilator market. And when it comes to the geographic perspective, we do continue to see the US and China as our two largest markets. We also expect to have a number of successful product launches here, coming from the innovation and therapy expansion initiatives that we have already kicked off. And I also want to point out that the growth projection here assumes that core current quality channels are solid, and that no new major issues evolve from the ongoing remediation and the launched cardiac assist and cardiopulmonary hardware. So we can then move to slide number nine, please. So we're moving on to Life Science. And this is the business area that accounts for about 15% of its net sales. And America is the largest market in EMEA. Margins have been a challenge in the past years here. And it's now below pre-pandemic levels. Uh, there's been a rather suppressed investment climate in bioprocessing. There has been a lot of destocking in this industry as well. And we're hopefully seeing the end of that now. So for 2024 through 2028, Life Science is expected to grow 6 to 10%. And this assumes that the normalization in biopharma takes place and that we return to a low to mid-teens growth in this subsegment. We also assume that capital goods will benefit from the growing GMP one industry. This is a trend that we are on right now. And we also expect the recovery in China, even if the timing of this is still a bit uncertain, especially when it comes to the biopharma side of Life Science. We also expect to continue to partner with key biopharma companies, and being part of their growth will be crucial for us on this journey. Within acquisitions, our focus is primarily on the bioprocessing space and geographically mainly in the US. So we can move to slide ten and look at surgical workflows. Surgical Workflows is about 35% of Getinge's net sales. And uh, we have close to half of that, about 35% in the Americas with 30% in the Americas. Margins here are now well above pre-pandemic levels. Uh, so for 2024 through 2028, Surgical Workflows is expected to grow 4 to 6%. Uh, the dynamic behind this projection is that we assume there will be low single-digit growth in capital equipment, and then in service, we expect double-digit growth in digital solutions, in infection control consumables, and also in some of the new segments that we're addressing here. And that's mainly low-temperature sterilization and endoscopy. Reprocessing in the US is expected to grow for Surgical Workflows, whereas China is expected to be a bit more challenging. And when it comes to acquisitions, the focus is primarily on targeting acquisitions in consumables and in digital. So this overview then boils down to the group financial targets for the coming years. So we can move to slide 11. And I will hand over to you again.

Unknown 1
12:50 - 16:41

Thank you. Materials. And as mentioned already, the situation with Cardiohelp and the HLS products in the US impacts our financial projections and targets mid-term. However, for the period 2024 to 2028, we feel confident, um, in that financial target of adjusted EPS growth above 12% on average throughout this period. We also remain with the same dividend policy as previously of 30 to 50% of net profits. Go to slide 12, please. In addition to our financial targets, we also update our sustainability targets. So these are now structured in line with the SRS standard for social environment and governance. Compared to our previous targets. I want to highlight two important points. Firstly, our quality-related target is changed to less than 1.5 audit findings per inspection. This is for increased usability and measurability. Secondly, our environmental targets are now linked to the Science-Based Targets initiative. Next slide please. As Mattias mentioned earlier, enhanced productivity will continue to be key for us in the years ahead. We have addressed, and we are continuing to address, several measures. For example, in relation to our successful EU MDR uplift program, we have reduced the number of product groups in our portfolio by more than 30%. Through Quality Value Engineering, we aim to get even better at developing the right products at the right cost, both from a competitive and a margin perspective. In addition to these continuous process improvements, we will potentially make structural cost adjustments depending on the progress within the cardiac assist and cardiopulmonary businesses. Next slide please. Zooming in then. What this means for the structurally motivated EBITDA margin, which has been quite volatile in the past years. Um, the positive contribution from mix, operational leverage, and cost absorption during the pandemic resulted in a 19.3% margin at the peak in 2020. This situation was reversed in the past years, with high inflationary cost pressure coupled with weakened demand for some of our high-margin products as well as in China, resulting in a level of approximately 12%. The recent decisions related to the balloon pump, CardioHelp, and HLS in the US have changed the conditions of the structurally motivated margin. We expect a delay before the margin picks back up again. Through normalization and our internal efforts, we project to close the gap to the line of 3 to 6% structurally motivated organic net sales growth. And this, in turn, means that the adjusted EBITDA margin is expected to be in the range of 16 to 19% at the end of this period in 2028. Assets are expected to be in the low to mid-20s, life science in the mid-teens, and surgical workflows in the low teens. Go to slide 15 please and back to you, Mattias.

Mattias Perjos
16:43 - 18:04

All right, thank you. I just want to sum up the key takeaways from today's call. So, we have decided to suspend promotional activities for CardioHelp and CardioSave in the US until safety concerns are addressed and the improvements receive FDA approval. Furthermore, we will inform all customers about the indications for the use of CardioHelp and we will continue to supply the installed base with intra-aortic balloons and HLS consumables, as well as continuing to service the hardware that's out there. We have reiterated and updated our financial targets, so we have increased the targets for adjusted EPS growth to above 12% CAGR during the 2024 to 2028 timeframe, and we maintain the same dividend policy of 30 to 50% of the net profit. We do realize that this is a fairly wide span. It's just in the wake of the events last week with the update from the FDA that we've had to widen the span and reduce it a bit from what might have been the case in the weeks before that. But, we are where we are, and we need to start from here. And I thank you for listening now. And we are happy to move to the Q&A part of this session. Thank you very much.

Operator
18:10 - 18:31

If you wish to ask a question, please dial Pound Key five on your telephone keypad to enter the queue. If you wish to withdraw your question, please dial Pound Key six on your telephone keypad. The next question comes from Oliver Weinberg from Kepler. Curious? Please go ahead.

Oliver Weinberg
18:34 - 19:28

Oh, yes. Thanks so much for taking my question. The first one would be on quality. So it sounds like these are not any kind of big issues and no new big findings. But obviously both the European and also the US regulators have indicated their kind of dissatisfaction with the kind of progress being made. So just can you share your perspective on these kind of developments? I mean, I think earlier you talked about your issues with suppliers, but is it just that, and also, how do you feel about potential additional quality actions? So you have to invest more into quality? And how do you think about the balance of business expertise and quality expertise on the top management board? That would be the first question. And then just secondly, I mean, obviously both echocardiography and cardiopulmonary are very critical devices for the US market. So what kind of risk do you see that the FDA is keen to push a new supplier into this market, like Abbott or so? Thank you.

Mattias Perjos
19:30 - 21:49

Yes. Thanks, Oliver. When it comes to the quality bit. Yes, I can definitely confirm, what I started with the quality overview, that first of all, the challenges that we're working through are confined to cardiopulmonary and cardiac assist. I do think that we have a good team in place right now with the changes that we've made recently. We have a new head of quality, John Englekey. He has been on board for a little less than two years. We've also reinforced the organization in different parts of acute care therapies and in the core quality organization itself. So I do feel that we have the right resources and competencies in place right now to work this through. And you're absolutely right that there were no new field actions required here from the work that we've been going through. So we've maintained a heightened level here in the wake of the quality backlog, the quality record backlog. But there's nothing new. Here in the last weeks or months, the work will continue. We have, as I pointed out in the presentation, about 10% of this work to go still. So we're a few weeks or months to go still here. And so far, we've not found anything else that we need to act on. So it is related to working through the challenges on the balloon pump itself. There are some technical and engineering challenges here that we need to work through making good progress, but it is rather complex work that is required. And on the HLS part, as I mentioned, we have already submitted for CE marks. We believe that we have a packaging solution in place for this product. So there's no change to that either. I hope that answers the quality part of the question when it comes to the FDA pushing new suppliers. Yes. I think it has been known for a while that they are not happy that we have the large market share that we do in the US. They think they're a bit too vulnerable because of this. They mentioned in the letter to healthcare providers as well that they are working actively with other suppliers to be able to fill the capacity that the market needs. So, this is also something that we are aware of.

Oliver Weinberg
21:51 - 22:08

Okay. And just to follow up, you expect no additional general quality costs for the organization. And just on this point, I mean, it sounds a bit surprising. You just filed for approval in Europe, but now the filing in the US is scheduled post the launch of the new device. What's the background here, please?

Mattias Perjos
22:09 - 22:26

Yeah, I think the background here is that there are very different regulatory frameworks in Europe and the US. So there will be a much more lengthy process in the US, we expect. So it's really just different ways of working with regulatory bodies.

Oliver Weinberg
22:30 - 22:31

And no additional quality costs.

Mattias Perjos
22:33 - 23:05

Now. We don't expect that now. We have nothing on the radar. We've added the resources that we believe we need. I think we have good capacity and competence to work through the challenges right now. And of course, we can't exclude additional quality costs if something comes up while we're working through this remaining 10% of the quality record backlog, or if something unexpected pops up when it comes to resolving the remediation work that we've already identified. But we don't see anything of that right now.

Oliver Weinberg
23:06 - 23:07

And I said, thank you very much.

Mattias Perjos
23:08 - 23:09

Thank you.

Operator
23:15 - 23:22

The next question comes from Rickard Kranz from Handelsbanken. Please go ahead.

Rickard Kranz
23:24 - 23:54

All right. Thank you for taking my question. So I have two if I could. Could you perhaps help us understand the phasing of the margin improvements and EPS growth? Should we then expect, you know, flat or negative development up until the 2025-2026 timeframe and then expect a very sharp improvement in 2026 and beyond, or help us interpret the messaging here. Thank you.

Unknown 2
23:56 - 23:57

Yeah.

Unknown 1
23:57 - 24:39

So we have included the fact that there's still a lot of uncertainty in this and how our customers will react. The coming months will provide more clarity on that. But we have, as you can see in the span here, worked with several scenarios, including the likely scenario. What we expect is a flattish trend initially, then picking up. The exact timing of that depends on. Our time plans to bring these new products to the market. We are confident in those plans, but then we have the regulatory approval process that impacts as well. But it's a fair assumption that you make that this year, and next year, will be more impacted, and then it will start to pick up.

Rickard Kranz
24:42 - 24:52

Okay, just a super quick follow-up then. So, is it fair to assume 2026 as a timeline for market approval and launch then for the upgraded hardware solutions?

Unknown 1
24:57 - 25:15

Yes, there are two different products and they have. One is set for 2025, and then we have the regulatory approval process following on that. Later in the year, early in 2026 and thereafter, following the approval process.

Rickard Kranz
25:18 - 25:44

Okay. I was curious to understand why you are looking to file for the HLS set in the US. After filing for the new hardware and not doing it faster. Since you already have a new filing in place for CE Mark. Is there something that needs to be done? Something additional for the US filing? Just trying to understand the sequence and timeline here. Thank you.

Mattias Perjos
25:45 - 26:17

Yeah, that's in line with what Oliver asked as well, earlier that it is a very different process. There are additional usability studies that we need to do. There are different demands when it comes to biocompatibility, for example. So it's just a lot more work to prepare for the filing in the US. So you're absolutely right that the product is actually ready. We don't expect to undertake any new development when it comes to the HLS advanced kit, but there is a lot of testing and documentation required for this and slightly different studies in the US.

Rickard Kranz
26:20 - 26:21

Thank you for taking my questions.

Mattias Perjos
26:22 - 26:22

Thank you.

Operator
26:27 - 26:33

The next question comes from Mattias Perjos from SEB. Please go ahead.

Sten Gustafsson
26:37 - 27:02

Hi. Thanks for taking my questions. The first one is on HLS where you are looking at 3 to 5% growth. If you could provide just some flavor in terms of growth for the different categories, maybe ventilate a little bit and some of the other products because it sounds a bit high, perhaps, given the outlook for the coming years, so to speak. So that's the first one.

Unknown 1
27:05 - 27:31

Okay. We don't disclose the different product categories and how we expect them to grow, but bear in mind that we do have a cardiopulmonary offering and a rather large one outside of the US as well. And there we see a different trend. We do expect to be able to capture some of these, um, changes that are happening in the ventilator market as well.

Sten Gustafsson
27:36 - 28:05

Thank you. And the next one is, uh, just a quick follow-up to Rickard and Oliver's questions here. So in terms of the HLS set, when can it be approved in the US? Because that follows the pathway for FDA approval. The hardware there, as I understand it. And also, if you could just give a background on the regulatory situation for HMO in China. I mean, how are authorities looking at HMO over there? That's the next one.

Mattias Perjos
28:07 - 29:01

Yeah. I think we can't give an exact timeline on the approval of HLS in the US. As I said, the product, the HLS Advanced, is developed, um, and it has already received the, um, approval. But the complexity when it comes to this additional work that needs to be done before the filing in the US, um, we can only say that it will be after we have, um, done the submission for PMA approval. I can't be more specific than that, um, right now. And it's really just that it's a different regulatory framework, different requirements in the US for this product. When it comes to China, I think there is generally a favorable, um, view on the market there. The, um, government and the authorities have pointed this out as a key area for, um, the future. We do see continued good demand for ECMO in China as well. So, um, overall positive.

Sten Gustafsson
29:04 - 29:40

Okay. And I will limit myself to one more question. If we look at the gross margin a bit. I mean, in 2023, two percentage point margin impacts from quality costs, as I understand it, from COGS impact. You have a bad mix. You grew fast in capital goods, life science, and surgical workflows. But if we look at the inflation of raw materials, etc., versus the lack of price increases, could you give us an understanding of how much of an impact that has been and the visibility of recovering that impact, let's say, in the coming two years? That's my last one.

Unknown 2
29:42 - 29:43

Yeah.

Unknown 1
29:43 - 30:19

So I will try to give some flavor of how we are addressing the different cost versus pricing developments. So we do see comparatively good pricing traction if we compare ourselves to our peers in our industry. However, from a margin perspective, up until recently, there has been a gap which has gradually been closed and we have a lag in the timing where we can implement price increases. So now we are moving towards margin neutral from material and pricing.

Sten Gustafsson
30:22 - 30:30

And when do you expect to move to a margin positive trajectory from that sort of price versus cost of raw materials?

Unknown 1
30:31 - 31:02

So, these recent events do influence our ability, obviously, for pricing in the US for these products, Cardiohelp and Cardiosave. That aside, and that is included in this scenario that we presented today. But that aside, we expect in the other product categories as well as in Life Science and Surgical Workflows towards the end of this year that we will move into margin positive.

Sten Gustafsson
31:04 - 31:05

Thank you very much.

Operator
31:12 - 31:18

The next question comes from Eric Castle from Danske Bank. Please go ahead.

Eric Castle
31:21 - 31:54

Hello. Good morning everyone. So first question, just some inquiries on the FDA and their sort of tone now. It seems a bit more serious. And they think that you're not really making the proper corrections. I understand that they can't really make any sort of product removal as it stands now with your market share. But do you think down the line that there is a risk of maybe a fine related to how you handle this or that? The FDA would try to make some sort of product removals? That's a fair question.

Mattias Perjos
31:56 - 32:32

Yeah. Thanks. We can't speculate on that. As I said when I went through the slides here with FDA, they have not asked us to do anything different than we're already doing. There are no new tasks given to us by the FDA. The letter is to healthcare providers, not to Getinge as well. I think it's important to be aware of that. So, there's nothing I can speculate on, whether it will be a fine or anything. It's really just the work that needs to be implemented here in the fastest way possible. And there's no disagreement with the FDA on that we're going.

Eric Castle
32:34 - 32:55

Okay. Thank you. And then you said the target is for 2028. Um, and I think the wording that you used, you know, using structural targets implies to me that there's a potential risk, like quality issues and maybe even constant decrease could continue for longer than you previously talked about. I mean, is that what you're intending to say or am I misinterpreting that?

Mattias Perjos
32:57 - 34:03

I don't think that was the intention. I think it is important to have a long-term view given that we are in a consent decree, and the way this works is that we need to finalize the remediation. So we've gone through the quality management system. That's where this remediation journey started. We now have a compliant quality management system implemented. We've been through a lot of the other remediation work related to our different facilities, processes, documentation, and also several products. And we are now down to two remaining product categories, which are cardiac assist and cardiopulmonary. So we need to get this work done. First. And you've seen some of the timelines for new products and finalizing the remediation of this. And it's only when we have done that, we can move to an observation period in the compliance date. And this observation period is completely up to the FDA to decide. So that's why I think it's important to have a long-term perspective on this. And that's the main reason we've gone with a five-year horizon.

Eric Castle
34:05 - 34:34

Okay. Thank you. And then just the last question. I mean, you're saying that you don't really know the magnitude of costs relating to accelerating the development of Cardiohelp and Cardiosave and basically the impacts of the next year when it comes to getting these products approved in the US and all that. I mean, I'm just wondering, why aren't you able to give any sort of ballpark figure how much this will cost to at least say if it will have any sort of significant impact or not?

Mattias Perjos
34:35 - 34:51

I hope I didn't say that. We don't know the cost of it because we do. I mean, we know very well the development cost for everything that's in our remediation program. So that is baked into both our current running cost and also the projections that we've just given.

Eric Castle
34:54 - 35:02

Okay, I guess my question is then why you haven't really decided to communicate? Um, how much of the impact is going to be of accelerated development, etc.?

Mattias Perjos
35:07 - 35:41

Yeah. I mean there's a reason, it's not something that we have planned to communicate. It's partly because of the reason why we haven't dissected some of the historic quality costs, either because you end up with some things that are clearly related, one clearly related to one of our initiatives and actions. But you also end up with something that is maybe partly related to development and improvement, but partly also structure. So it becomes a very tricky exercise to dissect this in a fair way.

Unknown 1
35:41 - 36:05

I think we can say that this is part of our ordinary, normal product development cost. But you do see already if you look at the Q1 report, for example, that we have some elevated R&D costs, which are then partly related to this and that we continue to see in the coming quarters until we reach the timelines that we talked about.

Eric Castle
36:07 - 36:08

Okay. Thank you very much.

Mattias Perjos
36:10 - 36:10

Thank you.

Operator
36:14 - 36:21

The next question comes from David J. Adlington from J.P. Morgan. Please go ahead.

David J. Adlington
36:25 - 37:18

Uh, morning, guys. I'm going to start off with a bit of an anecdote that will turn into a question. So your quality issues first emerged while I was on a babymoon ahead of the birth of my third child. I remember it well because I spent a day on conference tours, much to the annoyance of my wife. That baby was born a couple of months later, and Daisy will celebrate her 10th birthday this summer. So we're a decade later, and we still have you operating under a consent decree, and we still have new emerging quality issues. So the first question is, why do you think you're still having these issues so much later on after such a long time? And what are you doing to change the quality culture? And then the second question is, uh, you reiterated your revenue guidance for this year despite the suspension of Cardiohelp and Cardiosave, and you've cited a potential negative impact from that. And it's too early to have a view on the magnitude. Is there therefore a risk that you will have to downgrade your full-year guidance later on this year? Thanks.

Mattias Perjos
37:19 - 39:30

Yeah. Thanks, David, and thanks for committing to be with us rather than your family. Well, it's, uh, I just want to highlight that there's, uh, there's no new issues again here. Uh, it's I think it's a common, uh, misunderstanding. If we get to hear there's a lot that there's new issues popping up. But these are not new issues. They are old sometimes, uh, five, ten-year-old, uh, issues. And even longer than that. So, yes, we've been under a consent decree since 2015. It is a very long, drawn-out, uh, time. Uh, we started the work with remediating the quality management system. That was the main, uh, uh, main finding at the time. And, uh, we put a compliance system in place. Then you go through everything else related to this, and we are now at the product remediation stage of this. And I say isolated now to two product categories cardiopulmonary and cardiac assist and the issues that we are addressing in those two categories. Now they are old issues. They're not new issues. They've become known now because we've gone through a long history of quality record backlogs. But they're not new issues. They've been there for many, many years. When it comes to quality culture, that's something that we've actively worked on since the last strategy review that we conducted in 2017. And not only quality culture, it's also the culture of continuous improvement, of having a long-term view on what we do to avoid making shortcuts in any work that we undertake. And that's something I think we've made a lot of good progress on. It's quite a different situation compared to five to ten years ago. So that perhaps covers the quality part of the question when it comes to your question about revenue guidance for this year, we've remained with the guidance that we've issued now: 2 to 5% for these two years, for 2024. We will monitor the development in the coming months and see what the behavior of customers and competitors and so on may be. I can't exclude a downgrade here, but we don't see that right now.

David J. Adlington
39:32 - 39:33

Okay. Thank you.

Operator
39:42 - 39:48

The next question comes from Robert Davies from Morgan Stanley. Please go ahead.

Robert Davies
39:51 - 40:47

Good morning. Thanks for taking my questions. My first question was just to be clear on the language that was used in the press release, which I think you put out yesterday evening around the structurally justified organic sales growth and margins. Is that essentially the targets that you would have set in place if these issues had not arisen? So, my first question is, is the 3 to 6% and 16 to 19% margin guidance what you would essentially have had in place if this issue hadn't arisen, and that's why you've got the 12% plus EPS guide? And then I guess just one specific question on life sciences, just in terms of the medium-term outlook there, what are you looking for in terms of early indications of returning to a more normalized level of profitability in that sector? Thank you.

Mattias Perjos
40:48 - 42:10

Yeah. Thanks, Robert. The first question, the answer is that the structurally motivated growth and the EBITA margin now include the bad news from last week. So, that's now part of the structure, if you like, so if we hadn't had that, we would have been probably at a slightly higher and less wide span as well. When it comes to Life Science, we're monitoring both from leading indicators like the volume of investments going into bioprocessing in general. And then, of course, looking at our own businesses when it comes to requests for proposals and conversion rates, to see that we can get a pickup in this part of the business. Very strongly linked to the bioreactor portfolio business, which has been the hardest hit in the last 1 to 2 years, but also closely monitoring the development when it comes to the sterile transfer part of what we do. So, that's another key area where we have our focus when it comes to the more capital-heavy part of life sciences. I think we already have pretty good visibility. And it's a very good dynamic in general, partly related to GLP-1, but also more broad-based, given that we have all the big pharma names as customers in this part of the business.

Robert Davies
42:12 - 42:49

Thank you. Maybe just one follow-up. Just so I'm clear in my own mind, concerning the timeline that you're internally following here to map out these earnings and growth targets. What are the key dates or timelines? You mentioned earlier on the call something coming in mid-2025 and then early 2026, in terms of solutions; is that the key timeline you're looking at? I guess I'm just trying to get a feel for where the risks are to this mid to long-term guidance and what we should be looking out for. In terms of signposts indicating whether we are on track, ahead of schedule, or behind schedule. Thank you.

Mattias Perjos
42:51 - 43:53

Yes, that's a correct interpretation. So, we have the ongoing development of code. You say that will be finalized in the middle of next year and then, uh, submitted for approval in the second half of next year. And then code two is to follow in the HLS kits based on this. So this is now us, focused. And it means that we need to go for a complete new 510k clearance. So in that sense, it's different compared to Europe where, for example, with Cardiohelp, we've been able to implement step-by-step improvements to ensure that the products are as patient-safe as they can be; in the US, it's a different approach. The FDA doesn't permit these kinds of stepwise upgrades. We need to do the whole package. So, therefore, it's a bit more drawn out in time there. And that's also why it's a different perspective when it comes to what we can promote. And selling in the US compared to outside of the US. So.

Robert Davies
43:55 - 43:56

And I said, okay, that's great. Thank you.

Operator
44:03 - 44:10

The next question comes from Sten Gustafsson from ABG Sundal Collier. First sentence.

Unknown 3
44:14 - 44:52

Good morning. A question regarding the consumables related to Cardiosave and Cardiohelp in the U.S. What have you assumed in terms of growth rates? Um, for those products in the U.S.? Do you see a risk that it would be negatively impacted as well, particularly if hospitals opt to buy hardware products from your competitors? But it would be interesting to hear your view on what you have assumed in terms of growth for those products.

Mattias Perjos
44:53 - 45:29

That we don't disclose growth rates of individual parts of the product ranges here. All in all, if you take all the cardiac pulmonary and cardiac assist businesses that we have, it's about 7% that is in the US. Uh, an important part of that is, of course, the HLS kits. The HLS kits, or captive to record your help, uh, to, uh, so, uh, customers need to change hardware as well before they can change to other consumables. So we don't disclose the individual numbers here by the product category.

Unknown 3
45:31 - 45:47

Okay, but if a hospital decides to change hardware, can they still buy your consumables or how does that work?

Mattias Perjos
45:48 - 45:58

It depends on what hardware they change to; some are more generic. You can use different consumables. So I can't give you a black and white answer on this.

Unknown 3
45:58 - 46:13

Okay. Uh, secondly, could you tell us the sales exposure for CardioSave and CardioHelp in the U.S.? In terms of hardware.

Mattias Perjos
46:15 - 46:34

Uh, no, not uh, I said the combined business of hardware and consumables is about 7% of our revenue in the US. Uh, the important part of this is, of course, the consumables business. So, the hardware is less, but we don't break that down any further.

Unknown 3
46:35 - 46:36

Okay. Thank you.

Operator
46:42 - 46:49

The next question comes from Rickard and Kranz from Handelsbanken. Please go ahead.

Rickard Kranz
46:51 - 47:12

Hi. Just a quick follow-up. So I understand. So will you pause all the promotional activities until you have approval for new products in place? Or when do you expect to be able to actively market the products? Again, just trying to understand a little bit on that side. Thank you.

Mattias Perjos
47:13 - 47:32

Yeah. It is difficult to put a timeline on this. What we need to do is to implement the work that has already been agreed with the FDA for a long time, and receive approval for those upgrades as well. So it's somewhat out of our hands how long this will take. So that's why we can't be more specific, unfortunately.

Rickard Kranz
47:34 - 47:44

Okay, but is it reasonable that you may be able to resume promotional activities when you have cleared 100% of the quality record backlog?

Mattias Perjos
47:45 - 48:31

Uh, no it's not. No, it's more important, the actual implementation of the improvements. So the improvements relate to the hardware platform. So the balloon pump itself - it's the packaging and the uplift of the HLS advanced kit as well to the standards that are applicable in the US when it comes to CardioHelp. There's no particular work that really needs to go into this product. It is existing, without any field safety actions in place right now, because the work with TÜV SÜD is also in the final stages of being developed. But the submission work for this is quite extensive.

Rickard Kranz
48:33 - 48:43

Okay. Clear. And did I understand it correctly, that about 7% of the combined franchise of U.S. sales and not group sales?

Unknown 2
48:45 - 48:45

No.

Mattias Perjos
48:46 - 48:57

No, it’s, uh, if you take cardiopulmonary and cardiac assist sales in the US, that makes up about 7% of, uh, of group, uh, sales.

Rickard Kranz
48:57 - 48:59

Very clear. And that's on a rolling 12-month basis.

Mattias Perjos
49:01 - 49:02

And it was the end. Yes.

Rickard Kranz
49:04 - 49:05

Okay.

Mattias Perjos
49:08 - 49:09

All right. Thank you.

Rickard Kranz
49:09 - 49:11

Thank you for taking my question.

Operator
49:19 - 49:25

There are no more questions at this time, so I hand the conference back to the speakers for any closing comments.

Mattias Perjos
49:28 - 49:41

Yes. Thank you very much. Thanks for attending the call today. Uh, we have already gone through the summary here, so nothing to add for more perspective. I thank you for the attendance and wish you a good rest of the day. Thank you.

Continue to the webcast
Revenio Group Oyj, Q3'26
Language: English11/12/2026, 1:00 PM
Jukka Kainulainen Good afternoon, and welcome to the Revenio Group Corporation Q3 Earnings Call. My name is Jouni Toijala. I am the CEO. And then, again today we have Jukka Kainulainen, our CFO, on th…
Kamux, Q3'26
Language: English11/12/2026, 9:00 AM
Katerina Heterant Good morning. Welcome to the Kamux Q3 results presentation. My name is Katerina Heterant and I am Head of Investor Relations at Kamux. Today we shall go through the Q3 results presen…
Koskisen, Webcast, Q3'26
Language: Finnish11/12/2026, 8:00 AM
Jukka Pahta Hyvää huomenta ja tervetuloa tähän osavuosikatsaustilaisuuteen! Koskisen tammi–syyskuun osavuosikatsaustilaisuuteen lähdetään otsikolla: Koskisen liikevaihdon kasvu jatkui. Kohonneet kusta…
Reaktor, Q3'26
Language: Finnish11/11/2026, 9:00 AM
Pekka Horo Oikein hyvää aamupäivää kaikille ja tervetuloa tähän meidän webcastiimme. Olen Pekka Horo, Reaktorin toimitusjohtaja, ja kanssani täällä on tänään Antti Akkanen, joka aloitti lokakuussa Rea…
Savox, Q3'26
Language: English11/10/2026, 11:00 AM
Paulina Tanila Our speakers today are CEO Jerry Kettunen and CFO Juha Järvi. Jerry will give an overview of Savox as a company and go through the highlights of the quarter. After that, Juha will conti…
Raisio Oyj, Webcast, Q3'26
Language: Finnish11/10/2026, 10:00 AM
Elli Siltala Hyvää marraskuista päivää Raisiosta! Ja tervetuloa Raision tammi-syyskuun 2026 osavuosikatsauksen webcastiin! Pahoittelut pienistä teknisistä haasteista, mitä meillä oli tässä alussa. Min…
Mandatum Oyj, Audiocast, Q3'26
Language: English11/10/2026, 9:00 AM
Lotta Borgström Good morning, everyone, and welcome to the Mandatum Q3 2026 audiocast. My name is Lotta Borgström from Investor Relations. Joining me today are our CEO, Petri Niemisvirta, and our CFO,…
Solar foods Go-to-market Update
Language: English11/9/2026, 12:00 PM
Maria Hello everyone, and welcome to the Solar Foods go-to-market update. My name is Maria and I'm here today with our CEO, Rami Jokela, and CFO and Deputy CEO, Ilkka Saura. Also with us today is Heli…
Outokumpu, Webcast, Q3'26
Language: English11/6/2026, 12:30 PM
Johan Welcome to the third quarter results webcast. I am responsible for investor relations. We will start with the presentation from our CEO, Kati ter Horst, and our CFO, Marc-Simon Schaar. After the…
Endomines, Webcast, Q3'26
Language: English11/5/2026, 1:00 PM
Andy Turpin Hello, everyone, and welcome to Endomines' third-quarter results webcast. Thanks for joining us today. My name is Andy Turpin and I am the Chief Communications Officer here at Endomines. A…
Lemonsoft Oyj, Q3'26 webcast
Language: English11/5/2026, 11:00 AM
Unknown 1 Welcome to the Lemonsoft Q3 results presentation. We will start with the presentation from CEO Alpo Luostarinen, followed by the Q&A. You can send your questions throughout the event via the…
Enersense, Webcast, Q3'26
Language: English11/5/2026, 10:30 AM
Liisa Tamminen Hello and welcome to the Enersense Q3 2026 results webcast. My name is Liisa Tamminen from Enersense Investor Relations. And with me here I have our CEO, Kari Sundbäck, and CFO, Jan-Elo…
Sitowise, Q3'26
Language: English11/5/2026, 10:00 AM
Mari Reponen Good day everyone, and welcome to the Sitowise Q3 2026 results audiocast. My name is Mari Reponen, and I am responsible for strategy and IR here at Sitowise. And today with me are our act…
Orthex, Webcast, Q3'26
Language: English11/5/2026, 9:00 AM
Alexander Rosenlew Good morning and welcome to the Orthex Interim Report. My name is Alexander Rosenlew and with me I have Saara Mäkelä, CFO, and Hanna Kukkonen, our CMSO. We will take you through the…
Suominen Oyj, Q3'26
Language: English11/5/2026, 8:30 AM
Anni Luoma Good morning, everyone, and welcome to the Suominen Q3 webcast. My name is Anni Luoma. I am the Manager of External Communications and Investor Relations at Suominen. Here with me are our P…
Lumo, Webcast, Q3'26
Language: English11/5/2026, 8:00 AM
Niina Saarto Good morning, all. Welcome. This is Lumo Homes plc's third quarter result webcast. I am Niina Saarto from Treasury and Investor Relations. Today I have two gentlemen here with me, namely…
CapMan, Webcast, Q3'26
Language: English11/5/2026, 7:30 AM
Charlotte Good morning and welcome to this presentation of CapMan. Q3 2026 interim report. Presenting today we have Pia Kåll, CEO of CapMan. And after the presentation, we will have a Q&A session. You…
Marimekko, Webcast, Q3'26
Language: English11/4/2026, 12:00 PM
Anna Good afternoon. My name is Anna and I am the IRO of Marimekko. It is my pleasure to welcome you to our Q3 webcast. With me, I have our president and CEO, Tiina Alahuhta, who will walk you through…
Administer, Webcast, Q3'26
Language: Finnish11/4/2026, 9:00 AM
Kimmo Herranen Welcome to the Administer Q3 2026 interim report. Results. Meillä on se alkaa. I am Kimmo Herranen. Kalle Lehtonen. Also. Kaarina og. Yelken. Kalle Lehtonen En el coco. Madan. Parannus.…
Kempower, Webcast, Q3'26
Language: English11/4/2026, 8:30 AM
Unknown 1 Powering the planet. Kempower. We charge our planet for the better. By powering the electric movement. We enable quick and scalable EV charging solutions for everyone and everywhere. We ma…